A UNIQUE PARTNERING OPPORTUNITY

DNDi is looking for a Korean CDMO/partner with which we can jointly apply for project funding from the RIGHT Fund in September 2021. The Korean CDMO/partner will play a major role in improving the COGS of a novel DNDi compound that will enable the realization of low production costs, driving affordable pricing and sustainable supply of the resulting medicine bringing equitable access for patients in need.

The collaboration is envisaged in two steps:
1. API process optimization to demonstrate the feasibility of improving cost efficiency (e.g., utilization of continuous manufacturing)
2. If feasibility is demonstrated, continuation to full API development and commercialization activities.

ABOUT DNDi

Created in 2003, the Drugs for Neglected Diseases initiative (DNDi) is an international, not-for-profit research and development organization developing new treatments for neglected patients. Acting in the public interest, DNDi bridges existing R&D gaps in essential drugs for various diseases by initiating and coordinating drug R&D projects in collaboration with the international research community, the public sector, the pharmaceutical industry, and other relevant partners. DNDi’s primary focus has been the development of drugs for the most neglected diseases, such as human African trypanosomiasis, visceral leishmaniasis (kala-azar), and Chagas disease, while considering engagement in R&D projects for other neglected patients (e.g. malaria, paediatric HIV, filarial infections, COVID patients in Africa).

Partnering with DNDi on behalf of neglected patients can be an optimal strategy for pharma companies and CRO/CDMO organizations to fulfil corporate social responsibility objectives, engage in the fields of global health and neglected disease R&D, and motivate employees interested in delivering medical innovations to people in need. See Annex 1.

DNDi as a foundation does not have its own funds. Since 2003, close to 60% of DNDi support has come from public institutions, slightly over 40% of the support has come from private sources.

ABOUT THE RIGHT FUND

The RIGHT Fund, established in July of 2018, is the first Public-Private Partnership (PPP) funding agency in Korea dedicated to supporting global health R&D. The three-way partnership is between the Government of Korea, Korean life science companies, and international funders. The RIGHT Fund provides a platform for the government and Korean life science industry to increase their contributions to global health and will serve as a vehicle for investment in R&D projects aimed at delivering tangible products to address disease burden in developing countries.

Page 1, Version 1.1
TIMELINES

<table>
<thead>
<tr>
<th>Process steps</th>
<th>Responsible party</th>
<th>Timelines</th>
</tr>
</thead>
<tbody>
<tr>
<td>Launch RFI</td>
<td>DNDi</td>
<td>25 June 2021</td>
</tr>
<tr>
<td>Send back the completed Excel questionnaire</td>
<td>Company</td>
<td>10 July 2021</td>
</tr>
<tr>
<td>Discussions under CDA with companies that provide satisfactory responses; budget preparation</td>
<td>DNDi; Company</td>
<td>mid-late July 2021</td>
</tr>
<tr>
<td>Partner selection</td>
<td>DNDi</td>
<td>early Aug 2021</td>
</tr>
<tr>
<td>Grant preparation</td>
<td>DNDi and Company</td>
<td>August-Sept 2021</td>
</tr>
</tbody>
</table>

CONTACT INFORMATION

Please kindly send any questions to both contacts below.

We request that you email the completed RFI Excel questionnaire to both contacts below.

<table>
<thead>
<tr>
<th>Contact persons</th>
<th>Title</th>
<th>Contact information</th>
</tr>
</thead>
</table>
| Christophine Marty Moreau | Senior Procurement Manager | Phone: +41 22 906 92 61  
                                 |                                       | Email: cmarty@dndi.org |
| Douglas Cary         | R&D Liaison            | Email: dcary@dndi.org                    |
WIN – WIN PROPOSITION

Why should companies collaborate with DNDi?

- Potential funding opportunities for neglected diseases
- Increasing networks with global health communities and expanded market presence in new geographies
- Enhanced reputation and staff motivation typically associated with global health projects
- New chemical entities to provide novel, easy-to-administer treatments
- Early development risk borne by DNDi and partners
- Working in tandem with expert groups in innovative collaboration models
- Leverage company’s low production cost advantage and DNDi’s clinical trial expertise in endemic countries
- DNDi’s global access activities help shape the market → viable commercial volumes at affordable price
- Social responsibility is increasing in demand from consumers, governments
- Initiatives improving access to medicines is considered “material” for growing number of companies
- Higher long-term performance: Top performers in certain ESG topics had higher financial performance